Release Date: May 07, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points BeiGene Ltd (NASDAQ:ONC) achieved GAAP profitability for the first time in Q1 2025, marking a significant financial milestone. The company reported a 49% increase in revenue year-over-year, reaching $1.1 billion in Q1 2025. Brukinsa, a BTK inhibitor, became the market leader in the US by revenue, surpassing competitors and demonstrating strong growth. BeiGene Ltd (NASDAQ:ONC) has a robust pipeline with over 10 proof of concept readouts expected across its solid tumor portfolio in 2025. The company has expanded its global reach, treating over 1.7 million cancer patients and achieving significant sales growth in Europe and other international markets. Negative Points The company faces challenges in navigating an increasingly complex global environment, including pricing pressures and trade policy uncertainties. There is potential risk associated with the IRA negotiations and the impact on pricing, particularly for Calquence starting in 2026. The company is still in the early stages of commercialization in some international markets, which may impact immediate revenue growth. BeiGene Ltd (NASDAQ:ONC) is investing heavily in R&D, which could strain financial resources if expected outcomes are not achieved. The competitive landscape in the BCL-2 inhibitor market is limited, with only a few key players, which could impact market penetration and growth. Q & A Highlights Warning! GuruFocus has detected 3 Warning Sign with ONC. Q: Can you explain how BeiGene's CDK4 program differs from existing treatments and its potential role in HR-positive breast cancer? Also, is there any interest in developing Brukinsa beyond oncology? A: Our CDK4 molecule is designed to be more potent and selective compared to existing treatments. We are aggressively moving towards phase 3 trials in second-line settings. Regarding Brukinsa, we are exploring its potential in autoimmune diseases, with a phase 3 trial ongoing for membranous nephropathy. Q: Can you provide insights into Brukinsa's performance in Q1 and the impact of Medicare Part D redesign? Also, can you break down Tembra's sales by region? A: Brukinsa's Q1 performance was influenced by typical seasonality and Medicare Part D redesign, which affected pricing dynamics. We don't provide a regional sales breakdown for Tembra, but we are encouraged by its progress in the US, especially with recent approvals and guideline listings. Q: What are the expectations for the Mangrove trial's interim analysis, and which proof-of-concept readouts are most exciting this year? A: The Mangrove trial is event-driven, and we anticipate results in the second half of the year. We have numerous exciting programs, but it's hard to single out favorites as many molecules are progressing well and expected to yield data this year. Story Continues Q: How do you view Brukinsa's long-term positioning in the CLL market, especially with upcoming competitor data? A: We are confident in Brukinsa's best-in-class status due to its superior efficacy and safety profile. We expect it to maintain and expand its market share, even with new competitor data, as continuous BTK therapy remains the best option for early lines of therapy. Q: What are the endpoints for the phase 2 data readout for Suroclax in refractory mantle cell lymphoma, and what is the typical review timeline in China? A: The phase 2 studies for both Suroclax and BTKCA focus on ORR and DOR as primary endpoints. In China, we have received priority review, and we anticipate potential approval in the first half of next year. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...